Submissions for variant NM_025137.4(SPG11):c.5381T>C (p.Leu1794Pro)

gnomAD frequency: 0.00011  dbSNP: rs201689565

Total submissions: 18

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Centre for Mendelian Genomics, University Medical Centre Ljubljana	RCV000414944	SCV000492879	likely pathogenic	Gait disturbance; Spastic paraparesis; Difficulty walking; Generalized hyperreflexia	2015-05-05	criteria provided, single submitter	clinical testing
Invitae	RCV000801301	SCV000941072	pathogenic	Hereditary spastic paraplegia 11	2024-01-29	criteria provided, single submitter	clinical testing	This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 1794 of the SPG11 protein (p.Leu1794Pro). This variant is present in population databases (rs201689565, gnomAD 0.01%). This missense change has been observed in individuals with hereditary spastic paraplegia (PMID: 26374131, 31407473; Invitae). ClinVar contains an entry for this variant (Variation ID: 374112). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SPG11 protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic.
Institute Of Human Genetics Munich, Klinikum Rechts Der Isar, Tu München	RCV000801301	SCV001149938	pathogenic	Hereditary spastic paraplegia 11	2018-07-10	criteria provided, single submitter	clinical testing
Centre for Mendelian Genomics, University Medical Centre Ljubljana	RCV000801301	SCV001368423	uncertain significance	Hereditary spastic paraplegia 11	2020-03-10	criteria provided, single submitter	clinical testing	This variant was classified as: Uncertain significance. The available evidence favors the pathogenic nature of this variant, however the currently available data is insufficient to conclusively support its pathogenic nature. Thus this variant is classified as Uncertain significance - favor pathogenic. The following ACMG criteria were applied in classifying this variant: PP3,PP5.
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen	RCV001268887	SCV001448123	pathogenic	not provided	2020-10-23	criteria provided, single submitter	clinical testing
Paris Brain Institute, Inserm - ICM	RCV000801301	SCV001451262	pathogenic	Hereditary spastic paraplegia 11		criteria provided, single submitter	clinical testing
Athena Diagnostics Inc	RCV001268887	SCV001474775	likely pathogenic	not provided	2020-10-19	criteria provided, single submitter	clinical testing	The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. Computational tools predict that this variant is damaging.
GeneDx	RCV001268887	SCV001795085	pathogenic	not provided	2023-03-23	criteria provided, single submitter	clinical testing	In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 27790088, 26374131, 31407473, 34426522, 31589614, 33098801, 35254204, 35872528, 36549973, 36139378, 35906604)
Genetic Services Laboratory, University of Chicago	RCV001268887	SCV002064389	likely pathogenic	not provided	2019-03-26	criteria provided, single submitter	clinical testing	DNA sequence analysis of the SPG11 gene demonstrated a c.5381T>C in exon 30, results in an amino acid change, p.Leu1794Pro. The p.Leu1794Pro change affects a highly conserved amino acid residue located in a domain of the SPG11 protein that is not known to be functional. The p.Leu1794Pro substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). This particular amino acid change has been reported in the compound heterozygous state with a truncating variant in three unrelated families with spastic paraplegia (Lynch et al., 2016). This sequence change has been described in the gnomAD database with a global population frequency of 0.0057% (dbSNP rs201689565).
Genome Diagnostics Laboratory, The Hospital for Sick Children	RCV001848737	SCV002105733	likely pathogenic	Hereditary spastic paraplegia	2018-05-01	criteria provided, single submitter	clinical testing
Molecular Genetics, Royal Melbourne Hospital	RCV000801301	SCV002503783	likely pathogenic	Hereditary spastic paraplegia 11	2021-03-11	criteria provided, single submitter	clinical testing	This sequence change is predicted to replace leucine with proline at codon 1794 of the SPG11 protein (p.Leu1794Pro). The leucine residue is highly conserved (100 vertebrates, UCSC), and not located in a known functional domain. There is a moderate physicochemical difference between leucine and proline. The variant is present in a large population cohort at a frequency of 0.006%, which is consistent with recessive disease (rs201689565, 16/281,906 alleles, 0 homozygotes in gnomAD v2.1 - PM2). The variant has been identified in a homozygous state and compound heterozygous with a second pathogenic allele in multiple cases diagnosed with complicated and pure hereditary spastic paraplegia, and segregates with the condition in one family (PMID: 26374131, 31407473 - PM3_Strong, PP1). Multiple lines of computational evidence predict a deleterious effect for the missense substitution (7/7 algorithms - PP3). Based on the classification scheme RMH ACMG Guidelines v1.2.1, this variant is classified as LIKELY PATHOGENIC . Following criteria are met: PM3_Strong, PM2, PP1, PP3.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV001848737	SCV003801201	pathogenic	Hereditary spastic paraplegia	2023-01-16	criteria provided, single submitter	clinical testing	Variant summary: SPG11 c.5381T>C (p.Leu1794Pro) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.7e-05 in 281906 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in SPG11 causing Hereditary Spastic Paraplegia, Type 11 (5.7e-05 vs 0.0011), allowing no conclusion about variant significance. c.5381T>C has been reported in the literature as a biallelic genotype in multiple individuals affected with Hereditary Spastic Paraplegia, Type 11 (e.g. Lynch_2016, Zech_2020, Krenn_2020, Peric_2022). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Ten ClinVar submitters have assessed the variant since 2014: one classified the variant as uncertain significance, six as likely pathogenic, and three as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Revvity Omics, Revvity	RCV001268887	SCV003820048	uncertain significance	not provided	2021-01-26	criteria provided, single submitter	clinical testing
3billion	RCV000801301	SCV003841386	likely pathogenic	Hereditary spastic paraplegia 11	2023-02-23	criteria provided, single submitter	clinical testing	The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.006%). Protein truncation variants are a common disease-causing mechanism. In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.90; 3Cnet: 0.63). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000374112). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline.
Ambry Genetics	RCV003168606	SCV003871801	pathogenic	Inborn genetic diseases	2023-01-09	criteria provided, single submitter	clinical testing	The c.5381T>C (p.L1794P) alteration is located in exon 30 (coding exon 30) of the SPG11 gene. This alteration results from a T to C substitution at nucleotide position 5381, causing the leucine (L) at amino acid position 1794 to be replaced by a proline (P). Based on data from gnomAD, the C allele has an overall frequency of 0.006% (16/281906) total alleles studied. The highest observed frequency was 0.012% (15/128650) of European (non-Finnish) alleles. This mutation has been reported in the homozygous and compound heterozygous state in individuals with spastic paraplegia (Lynch, 2015; Krenn, 2020; Doleckova, 2022; Peri, 2022). It was also identified in the homozygous state in an individual with childhood-onset dystonia (Zech, 2020) and in the heterozygous state in an individual with amyotrophic lateral sclerosis with no second SPG11 variant (Krüger, 2016). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic.
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden	RCV001268887	SCV004026402	likely pathogenic	not provided	2023-06-14	criteria provided, single submitter	clinical testing	PM3, PP4, PP3, PM2_SUP, PP1
UM ALS/MND Lab, University Of Malta	RCV003105892	SCV002555582	uncertain significance	Amyotrophic lateral sclerosis		no assertion criteria provided	research
GenomeConnect - Invitae Patient Insights Network	RCV003483611	SCV004228695	not provided	Hereditary spastic paraplegia 11; Charcot-Marie-Tooth disease axonal type 2X; Juvenile amyotrophic lateral sclerosis		no assertion provided	phenotyping only	Variant interpreted as Pathogenic and reported on 12-19-2020 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information.